India's Pharmaceutical Industry: Growth and Regulatory Challenges

Introduction

India's pharmaceutical industry is the third-largest in the world by volume and the 11th largest by value. Known as the 'pharmacy of the world', India supplies over 60% of global vaccines, 25% of all generic medicines in the US, and meets 80% of Africa's generic drug demand. The industry is currently valued at approximately USD 50 billion with exports exceeding USD 25 billion annually.

Historical Evolution

• 1901-1947: Limited manufacturing; dominated by foreign multinationals
• 1950s-1970s: Public sector entry (HAL, Bengal Chemicals); focus on basic drugs
• 1970: Indian Patents Act - product patents abolished, only process patents allowed (enabled reverse engineering)
• 1971: Drug Price Control Order (DPCO) - price regulation of essential medicines
• 1990s: Liberalisation opened the sector; rapid growth of generics
• 2005: TRIPS compliance - product patents reintroduced; shift toward innovation
• 2020-present: Focus on API self-reliance, R&D, and biosimilars

Key Segments

Generics

• India's core strength; 70% of the market by value
• Abbreviated New Drug Applications (ANDA) filings: India is the largest filer in the US
• Companies: Sun Pharma, Dr Reddy's, Cipla, Aurobindo, Lupin

Active Pharmaceutical Ingredients (APIs)

• India accounts for ~18% of global API...